PFIZER INC Operating Lease, Payments
PFIZER INC (PFE) reported Operating Lease, Payments of $471.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-02-26
- PFIZER INC operating lease, payments for the quarter ending 2019-12-31 was $94.00M.
- PFIZER INC operating lease, payments for the quarter ending 2019-09-29 was $88.00M.
- PFIZER INC operating lease, payments for the quarter ending 2019-06-30 was $78.00M.
- PFIZER INC operating lease, payments for the quarter ending 2019-03-31 was $78.00M.
- PFIZER INC operating lease, payments for fiscal 2025 was $471.00M, a 21.63% decline from fiscal 2024.
- PFIZER INC operating lease, payments for fiscal 2024 was $601.00M, a 19.22% decline from fiscal 2023.
- PFIZER INC operating lease, payments for fiscal 2023 was $744.00M, a 20.58% increase from fiscal 2022.
- PFIZER INC operating lease, payments for fiscal 2022 was $617.00M, a 59.43% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $471.00M 10-K · filed 2026-02-26 | ||||
| 2024-12-31 | $601.00M 10-K · filed 2026-02-26 | ||||
| 2023-12-31 | $744.00M 10-K · filed 2026-02-26 | ||||
| 2022-12-31 | $617.00M 10-K · filed 2025-02-27 | ||||
| 2021-12-31 | $387.00M 10-K · filed 2024-02-22 | ||||
| 2020-12-31 | $333.00M 10-K · filed 2023-02-23 | $334.00M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | $94.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $182.00M derived: sum of 2 quarters · filed 2022-02-24 | $260.00M derived: sum of 3 quarters · filed 2022-02-24 | $338.00M 10-K · filed 2022-02-24 | $346.00M 10-K · filed 2020-02-27 |
| 2019-09-29 | $88.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $166.00M derived: sum of 2 quarters · filed 2019-11-07 | $244.00M 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $78.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $156.00M 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | $78.00M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |